Role of Dipeptidyl Peptidase IV/CD26 in Inflammatory Bowel Disease

Detel, Dijana; Pučar, Lara Batičić; Pugel, Ester Pernjak; Kučić, Natalia; Buljević, Sunčica; Sinčić, Brankica Mijandrušić; Peršić, Mladen; Varljen, Jadranka

doi:10.5772/29285

Cited by 2 publications

(1 citation statement)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the relationship between DPPIV and inflammatory bowel disease (IBD) has been determined in a vast number of publications. ,− However, the defined role of DPPIV in the process of IBD remains unclear, and several mechanisms have been proposed, including the changing of the immune response at systemic and local levels , and the degradation of glucagon-like peptide-2 (GLP-2), , a potent and specific gastrointestinal growth factor. Although there are still some inconsistencies, most studies observed that DPPIV inhibition could lead to the alleviation of IBD, ,− suggesting a potential and novel approach to treat IBD.…”

Section: Conclusion and Discussionmentioning

confidence: 99%

Discovery of Highly Polar β-Homophenylalanine Derivatives as Nonsystemic Intestine-Targeted Dipeptidyl Peptidase IV Inhibitors

Huang¹,

Ning²,

Wang³

et al. 2019

J. Med. Chem.

View full text Add to dashboard Cite

Although intensively expressed within intestine, the precise roles of intestinal dipeptidyl peptidase IV (DPPIV) in numerous pathologies remain incompletely understood. Here, we first reported a nonsystemic intestine-targeted (NSIT) DPPIV inhibitor with β-homophenylalanine scaffold, compound 7, which selectively inhibited the intestinal rather than plasmatic DPPIV at an oral dosage as high as 30 mg/kg. We expect that compound 7 could serve as a qualified tissue-selective tool to determine undetected physiological or pathological roles of intestinal DPPIV.

show abstract